20 / 24
CEDIRANIB Y ASTS
•
Median % change in TMLs at 24 weeks was −8.3%
on cediranib versus +13.4% on placebo, one-sided
p = 0.0013 (RR 21% vs 0% placebo)
•
Median PFS was 10.8 months on cediranib versus
3.7 months on placebo (HR of 0.58 in favour of
cediranib, p=0.056)
•
PFS at 12 months was 47.7% on cediranib versus
22.5% on placebo
•
OS at 12 months was 94% on cediranib v 66% on
placebo, in spite of crossover on progression